Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Idarucizumab rapidly reverses dabigatran anticoagulation

Researchers find that idarucizumab effectively counteracts the workings of anticoagulant dabigatran in emergency situations.

Agents that can reverse the effects of oral anticoagulants could improve the risk-benefit profile of thrombosis-prevention therapy through use in situations such as uncontrolled bleeding or a need for emergency surgery.

In a study in The New England Journal of Medicine (online, 11 July 2017), researchers intravenously administered idarucizumab, a monoclonal antibody that binds to and reverses the anticoagulant dabigatran, to 301 dagibatran-treated patients with uncontrolled bleeding and 202 undergoing an urgent procedure[1].

They found that, after four hours, the median maximum reversal of dabigatran was 100% (95% confidence interval, 100 to 100). Uncontrolled bleeding stopped in a median of 2.5 hours and the median time to emergency procedure initiation was 1.6 hours, with 93.4% of these patients having normal perioperative haemostasis. Furthermore, there were no adverse drug-related safety signals in the 503 patients.

The researchers say the results demonstrate that idarucizumab can rapidly reverse dabigatran’s effects in emergency situations but post-marketing surveillance will be needed to further assess its safety.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203333

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • 3D structure of the anticoagulant, dabigatran

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.